Gumetinib is an oral small-molecule MET inhibitor, primarily indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. The standard dosage is 200 mg orally once daily, which can be taken with or without food, and the tablet must be swallowed whole. The specific dosage should be adjusted by physicians based on the patient’s individual conditions.
Dosage and Administration Method
1.Standard Dosage
The recommended initial dose is 200 mg once daily, usually administered as a single oral dose, until disease progression or intolerable toxicity occurs.
2.Administration Method
Swallow the tablet whole; do not crush or chew it.
It may be taken with or without food, but the daily administration time must be fixed to ensure stable blood drug concentration.
Dose Adjustment
In case of severe adverse reactions (e.g., hepatic injury, interstitial lung disease, etc.), dose adjustment shall be performed based on the physician’s assessment:
1.First dose reduction: Decrease to 150 mg once daily.
2.Second dose reduction: Further decrease to 100 mg once daily.
3.If lower doses are intolerable: Permanent discontinuation of the drug is required.
Precautions
1.Follow Doctor’s Instructions for Medication Use
Gumetinib is a prescription-only medicine. It must be used strictly in accordance with the physician’s guidance, and the dosage must not be increased, decreased, or discontinued without authorization.
2.Monitoring and Examination
During the treatment period, regular monitoring of liver function, blood routine, and pulmonary symptoms is required.
Immediate medical attention should be sought if severe reactions such as dyspnea, persistent fever, or jaundice occur.
3.Special Populations
Caution should be exercised when administering to patients with hepatic or renal impairment, and the dosage may need to be adjusted.
It is contraindicated for pregnant women, lactating females, and women planning pregnancy.
4.Drug Interactions
Gumetinib may interact with strong CYP3A4 inducers or inhibitors, which could affect the therapeutic effect or increase toxicity. If combination therapy with other drugs (e.g., antiepileptic drugs, antibiotics, etc.) is needed, the physician must be informed in advance.
Medical Guidance
1.Prior to medication use, confirmation of MET exon 14 skipping mutation through gene testing is required.
2.Regular follow-up visits should be conducted during the treatment period, and the physician will evaluate the efficacy and safety of the treatment.
3.If a dose is missed, do not take a make-up dose; take the next dose at the originally scheduled time.
